Bouma M,Nuijen B,Jansen M T,et al. A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A[J]. Int J Pharm,2002,248(1/2): 239.
[2]
Bouma M,Nuijen B,Sava G,et al. Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A[J]. Int J Pharm,2002,248(1/2): 247.
[3]
Vargiu A V,Robertazzi A,Magistrato A,et al. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations[J]. J Phys Chem B,2008,112(14): 4401.
[4]
Besker N,Coletti C,Marrone A,et al. Aquation of the ruthenium-based anticancer drug NAMI-A: a density functional study[J]. J Phys Chem B,2008,112(13): 3871.
Bratsos I,Bergamo A,Sava G,et al. Influence of the anionic ligands on the anticancer activity of Ru(Ⅱ)-dmso complexes: kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors[J]. J Inorg Biochem,2008,102(4): 606.
[14]
Alessio E,Mestroni G,Bergamo A,et al. Ruthenium antimetastatic agents [J]. Curr Top Med Chem,2004,4(15): 1525.
Bergamo A,Messori L,Piccioli F,et al. Biological role of adduct formation of the ruthenium(Ⅲ) complex NAMI-A with serum albumin and serum transferrin[J]. Invest New Drugs,2003,21(4): 401.
[17]
Pluim D,van Waardenburg R C,Beijnen J H,et al. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines[J]. Cancer Chemother Pharmacol,2004,54(1): 71.
[18]
Sava G,Pacor S,Bergamo A,et al. Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition[J]. Chem Biol Interact,1995,95(1/2): 109.
[19]
Sava G,Capozzi I,Bergamo A,et al. Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex[J]. Int J Cancer,1996,68(1): 60
Heffeter P,Bock K,Atil B,et al. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339[J]. J Biol Inorg Chem,2010,15(5): 737.
[22]
Messori L,Orioli P,Vullo D,et al. A spectroscopic study of the reaction of NAMI,a novel ruthenium(Ⅲ)anti-neoplastic complex,with bovine serum albumin[J]. Eur J Biochem,2000,267(4): 1206.
[23]
Chen J,Chen L,Liao S,et al. A theoretical study on the hydrolysis process of the antimetastatic ruthenium(Ⅲ) complex NAMI-A[J]. J Phys Chem B,2007,111(27): 7862.
[24]
Bacac M,Hotze A C,van der Schilden K,et al. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation[J]. J Inorg Biochem,2004,98(2): 402.
[25]
Frausin F,Scarcia V,Cocchietto M,et al. Free exchange across cells,and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cells[J]. J Pharmacol Exp Ther,2005,313(1): 227.
